MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation.
[1] Zonta F, et al. Blood. 2015 Jun 11;125(24):3747-55.
















